#1 Clinical Trials Search in Europe

Dermatophagoides Farinae Extract

This article discusses clinical trials investigating the use of Sublingual MM09, a drug containing Dermatophagoides Farinae Extract and Dermatophagoides Pteronyssinus Extract, for treating allergies to house dust mites. The trials focus on patients with moderate to severe rhinitis/rhinoconjunctivitis, with or without mild to moderate controlled allergic asthma. The study aims to assess the efficacy and safety of this sublingual immunotherapy compared to a placebo.

Table of Contents

What is Dermatophagoides Farinae Extract?

Dermatophagoides Farinae Extract is a medical treatment derived from house dust mites. It is used in a type of therapy called sublingual immunotherapy (SLIT) to treat allergies caused by these microscopic creatures[1]. The treatment is administered as a sublingual spray, which means it’s sprayed under the tongue.

This extract is often used in combination with another similar extract called Dermatophagoides Pteronyssinus Extract. Together, these extracts target the two most common species of house dust mites that cause allergies in humans[1].

Medical Conditions Treated

Dermatophagoides Farinae Extract is used to treat several allergic conditions related to house dust mite allergies, including:

  • Allergic rhinitis: This is inflammation of the inside of the nose caused by an allergen, such as house dust mites. It’s often called “hay fever.”
  • Allergic rhinoconjunctivitis: This condition affects both the nose and eyes, causing symptoms in both areas.
  • Allergic asthma: This is a type of asthma triggered by inhaling allergens like house dust mites.

The treatment is specifically designed for people with moderate to severe symptoms of these conditions[1].

How It Works

Sublingual immunotherapy with Dermatophagoides Farinae Extract works by gradually exposing your immune system to small amounts of the allergen (house dust mite proteins). Over time, this exposure can help your body become less sensitive to the allergen, reducing your allergic reactions[1].

The treatment is administered as a spray under the tongue, where it’s absorbed into your bloodstream. This method is considered safer and more convenient than traditional allergy shots.

Clinical Trial Details

A clinical trial is currently underway to evaluate the effectiveness and safety of this treatment. Here are some key details about the trial:

  • It’s a Phase III clinical trial, which means it’s in an advanced stage of testing[1].
  • The trial is randomized, double-blind, and placebo-controlled. This means participants are randomly assigned to either the treatment or a placebo group, and neither the participants nor the researchers know who is in which group during the study[1].
  • The treatment dose is 30,000 TU/mL (TU stands for Therapeutic Units, a measure of the allergen concentration)[1].
  • The treatment is administered for 12 months[1].
  • The study aims to evaluate both the effectiveness and safety of the treatment[1].

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key eligibility factors include:

  • Age: Participants must be between 12 and 65 years old[1].
  • Diagnosis: Participants must have a confirmed diagnosis of moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mites. Some participants may also have mild to moderate controlled asthma[1].
  • Allergy tests: Participants must have positive skin prick tests and blood tests showing they are allergic to house dust mites[1].
  • Symptom severity: Participants must have moderate to severe symptoms, as measured by a specific scoring system[1].

There are also several exclusion criteria, such as having certain other medical conditions or having received immunotherapy in the recent past[1].

Potential Benefits

If proven effective, this treatment could offer several benefits for people with house dust mite allergies:

  • Reduced allergy symptoms in the nose, eyes, and lungs[1].
  • Decreased need for allergy medications[1].
  • Improved quality of life[1].
  • Potential reduction in asthma symptoms and exacerbations for those with allergic asthma[1].

Safety and Side Effects

The clinical trial is designed to carefully monitor the safety of the treatment. While specific side effects for this particular treatment are not yet known, sublingual immunotherapy in general is considered to be safer than traditional allergy shots[1].

Common side effects of sublingual immunotherapy can include mild itching or swelling in the mouth. More serious allergic reactions are rare but possible, which is why the treatment is typically started under medical supervision[1].

It’s important to note that this treatment is still being studied, and all potential risks and benefits are not yet fully known. If you’re interested in this treatment, you should discuss it with your allergist or healthcare provider.

Aspect Details
Study Drug Sublingual MM09 (Dermatophagoides Farinae Extract, Dermatophagoides Pteronyssinus Extract)
Target Condition Moderate to severe rhinitis/rhinoconjunctivitis with or without mild to moderate controlled allergic asthma
Study Type Phase III, randomized, double-blind, placebo-controlled multicenter clinical trial
Primary Objective Evaluate efficacy of Sublingual MM09 compared to placebo over 12 months
Key Inclusion Criteria Age 12-65, positive skin prick test to house dust mites, specific IgE ≥ 3.5 kU/L, RCSMS ≥ 3 out of 6
Key Exclusion Criteria Recent immunotherapy, severe uncontrolled asthma, pregnancy, certain medical conditions
Primary Endpoint Mean daily RCSMS during the last 4 weeks of treatment
Secondary Endpoints Individual symptom and medication scores, quality of life, immunological parameters, safety assessments

FAQ

  • What is Sublingual MM09? Sublingual MM09 is an investigational drug containing extracts from two types of house dust mites: Dermatophagoides Farinae and Dermatophagoides Pteronyssinus. It is administered as a sublingual spray solution for treating allergies to house dust mites.
  • Who can participate in this clinical trial? The trial is open to patients aged 12-65 years with moderate to severe rhinitis/rhinoconjunctivitis, with or without mild to moderate controlled allergic asthma, caused by house dust mites. Participants must meet specific criteria, including a positive skin prick test and specific IgE levels to house dust mites.
  • What is the main goal of this clinical trial? The primary objective is to evaluate the efficacy of Sublingual MM09 compared to a placebo when administered for 12 months in treating allergies to house dust mites.
  • How is the effectiveness of the treatment measured? The main measure of effectiveness is the Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score (RCSMS) during the last 4 weeks of treatment. Other measures include individual symptom and medication scores for rhinitis/rhinoconjunctivitis and asthma, quality of life assessments, and immunological parameters.
  • What are some of the exclusion criteria for this trial? Participants are excluded if they have received recent immunotherapy for the tested allergens, have severe uncontrolled asthma, are pregnant or breastfeeding, have certain severe medical conditions, or are taking specific medications that could interfere with the study results.

Ongoing Clinical Trials on Dermatophagoides Farinae Extract

  • Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

    Recruiting

    3 1
    Investigated drugs:
    Portugal Spain

  • Skin Prick Test Diagnostic Accuracy Study in Patients with Dermatophagoides pteronyssinus and Dermatophagoides farinae Allergy Using Dermatophagoides pteronyssinus Extract and Dermatophagoides farinae Extract

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Spain

  • A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

    Not yet recruiting

    3 1 1
    Investigated drugs:
    Spain

Glossary

  • Rhinitis: Inflammation of the nasal passages, often causing symptoms such as sneezing, runny nose, and nasal congestion.
  • Rhinoconjunctivitis: A combination of rhinitis and conjunctivitis, where both the nasal passages and eyes are affected, causing symptoms like sneezing, itchy eyes, and watery eyes.
  • Sublingual immunotherapy: A form of allergy treatment where small amounts of allergens are placed under the tongue to help the body build tolerance to the allergen over time.
  • Dermatophagoides Farinae: A species of house dust mite that is a common cause of allergies in humans.
  • Dermatophagoides Pteronyssinus: Another species of house dust mite that frequently causes allergic reactions in humans.
  • IgE (Immunoglobulin E): An antibody that plays a crucial role in allergic responses. High levels of specific IgE can indicate an allergy to a particular substance.
  • Skin prick test: A method used to diagnose allergies by placing a small amount of a suspected allergen on the skin and then pricking the skin to allow the substance to enter. A positive reaction indicates an allergy.
  • RCSMS (Rhinitis/Rhinoconjunctivitis Combined Symptom and Medication Score): A measure used to assess the severity of allergy symptoms and the amount of medication needed to control these symptoms.
  • Placebo: An inactive substance that looks like the real medication but contains no active ingredients. It is used as a control in clinical trials to compare against the effects of the actual drug being tested.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sublingual-mm09-for-patients-aged-12-65-with-allergies-to-house-dust-mites-and-rhinitis-rhinoconjunctivitis-with-or-without-asthma/